Home > Neurology > AAN 2022 > Multiple Sclerosis > Favourable additional safety data for ofatumumab

Favourable additional safety data for ofatumumab

Presented By
Prof. Stephen Hauser, University of California, CA, USA
Presented by
Stephen Hauser University of California
Conference
AAN 2022
Trial
Phase 3, ALITHIOS
After up to 4 years of treatment, ofatumumab was still well tolerated in patients with relapsing multiple sclerosis (RMS); no new safety issues were identified. This was concluded from updated results of the ongoing, open-label, umbrella extension ALITHIOS trial. Ofatumumab is a fully-human, anti-CD20 monoclonal antibody developed for the treatment of adult RMS patients; the 20 mg dose is self-administered subcutaneously once a month [1]. Ofatumumab treatment up to 30 months was previously shown to have a favourable safety profile and to be generally well tolerated [2]. Cumulative data for up to 4 years of ofatumumab treatment were presented by Prof. Stephen Hauser (University of California, CA, USA) [3,4]. Patients had completed the core ASCLEPIOS I/II (NCT02792218,


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on